Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes
Abstract
Non-muscle-invasive bladder cancer (NMIBC) patients receive frequent monitoring because ≥ 70% will have recurrent disease. However, screening is invasive, expensive, and associated with significant morbidity making bladder cancer the most expensive cancer to treat per capita. There is an urgent need to expand the understanding of markers related to recurrence and survival outcomes of NMIBC.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 21, 2022
- Source ID
- 10.1186/s13148-022-01234-6
Entities
People
- Angeline S. Andrew
- Annette M Molinaro
- Brock C Christensen
- Devin C Koestler
- Ji-Qing Chen
- John D. Seigne
- John K Wiencke
- Karl T. Kelsey
- Lucas A. Salas
- Margaret R. Karagas
Organizations
- Congressionally Directed Medical Research Programs
- National Institutes of Health